ArticleClinical and translational gastroenterology2013
Helicobacter Pylori "Test-and-Treat" Strategy for Management of Dyspepsia: A Comprehensive Review.
Article in Clinical and translational gastroenterology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 1 synthesis or guideline pooled it, 79 citations in OpenAlex.
- First regional consensus on the management ofWorld journal of gastroenterology · 2025Guideline
- Comparable tolerability, symptom worsening, and treatment completion rates among different Helicobacter pylori eradication regimens in children.BMC infectious diseases · 2026Article
- Acid peptic disorder compass: An Indian expert consensus on comprehensive management.World journal of gastrointestinal pharmacology and therapeutics · 2026Review
- VTH BRAZILIAN CONSENSUS CONFERENCE ON HELICOBACTER PYLORI INFECTION.Arquivos de gastroenterologia · 2026Article
- Review
- Clinical Pathologic Profiles ofJournal of clinical medicine · 2025Article
- A survey of practice patterns and adherence to national and international guidelines on the management of Helicobacter pylori infection among gastroenterologists and gastroenterology fellows in India.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2025Article
- Review
- Epidemiology, pathogenicity, risk factors, and management ofBiomolecules & biomedicine · 2024Review
- Clinical evaluation of a real-time PCR assay for diagnosis ofInternational journal of clinical and experimental pathology · 2024Article
- Article
- Management of dyspepsia and Helicobacter pylori infection: the 2022 Indonesian Consensus Report.Gut pathogens · 2023Review
- Helicobacter pylori infection.Nature reviews. Disease primers · 2023Review
- The impact ofFrontiers in cellular and infection microbiology · 2023Article
- Evaluation of a New Monoclonal Chemiluminescent Immunoassay Stool Antigen Test for the Diagnosis ofJournal of clinical medicine · 2022Article
- Diagnostic Challenges ofCanadian journal of gastroenterology & hepatology · 2022Article
- Empirical vs. Susceptibility-Guided Treatment ofFrontiers in microbiology · 2022Article
- Assessment of the diagnostic accuracy and relevance of a novel ELISA system developed for seroepidemiologic surveys of Helicobacter pylori infection in African settings.PLoS neglected tropical diseases · 2021Article
- Cost-effectiveness modelling of use of urea breath test for the management ofBMJ open gastroenterology · 2021Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesDeciding on whether the Helicobacter pylori test-and-treat strategy is an appropriate diagnostic-therapeutic approach for patients with dyspepsia invites a series of questions. The aim present article addresses the test-and-treat strategy and attempts to provide practical conclusions for the clinician who diagnoses and treats patients with dyspepsia.
methodsBibliographical searches were performed in MEDLINE using the keywords Helicobacter pylori, test-and-treat, and dyspepsia. We focused mainly on data from randomized controlled trials (RCTs), systematic reviews, meta-analyses, cost-effectiveness analyses, and decision analyses.
resultsSeveral prospective studies and decision analyses support the use of the test-and-treat strategy, although we must be cautious when extrapolating the results from one geographical area to another. Many factors determine whether this strategy is appropriate in each particular area. The test-and-treat strategy will cure most cases of underlying peptic ulcer disease, prevent most potential cases of gastroduodenal disease, and yield symptomatic benefit in a minority of patients with functional dyspepsia. Future studies should be able to stratify dyspeptic patients according to their likelihood of improving after treatment of infection by H. pylori.
conclusionsThe test-and-treat strategy will cure most cases of underlying peptic ulcer disease and prevent most potential cases of gastroduodenal disease. In addition, a minority of infected patients with functional dyspepsia will gain symptomatic benefit. Several prospective studies and decision analyses support the use of the test-and-treat strategy. The test-and-treat strategy is being reinforced by the accumulating data that support the increasingly accepted idea that "the only good H. pylori is a dead H. pylori".
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.